StockNews.AI
REGN
StockNews.AI
26 days

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

1. Regeneron announces winners of the 13th Regeneron Prize for Creative Innovation. 2. The prize encourages creativity among early-career biomedical researchers. 3. Winners receive $50,000 and their institutions get $5,000 grants. 4. Regeneron emphasizes commitment to STEM and early science education. 5. The company has awarded nearly $2 million since the prize started.

8m saved
Insight
Article

FAQ

Why Bullish?

Recognition of innovative research enhances Regeneron’s reputation for fostering talent. Historical data shows awards often correlate with increased interest and investment in biotech firms.

How important is it?

The article highlights Regeneron's commitment to innovation, which is crucial for biotech market positioning. This commitment can enhance investor confidence and attract talent while enabling potential future successes in drug development.

Why Long Term?

Cultivating young scientists could lead to future breakthroughs, positively impacting Regeneron’s long-term growth. Innovations by prize winners could contribute to pipeline development in the coming years.

Related Companies

BIIBAMGNVRTXGILDSNY
July 24, 2025 07:30 ET  | Source: Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their “dream projects” in biomedical science to a panel of Regeneron’s leading scientists, who evaluate the proposals for scientific merit, creativity and originality.This year’s winners are Alissandra L. Hillis, Ph.D., and Sreekar Mantena. Dr. Hillis is a postdoctoral fellow at the Massachusetts Institute of Technology (MIT), and Mr. Mantena is an M.D.-Ph.D. candidate, enrolled in the joint Harvard Medical School-MIT program and nominated by Broad Institute. Each winner has been awarded $50,000, in addition to a $5,000 grant to their home institution to support its seminar series. Seven other finalists each received $5,000 awards. “Regeneron has changed the practice of medicine by dreaming big and inventing game-changing technologies – from the soluble receptor technology that helps save the vision of millions, to the VelocImmune® humAb mouse that enabled treatments helping people suffering from allergic diseases and cancer,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron, and principal inventor of Regeneron’s 12 FDA-approved medicines. “The Regeneron Prize encourages young scientists to dream big, challenge what’s possible, and recognize their potential to bring forward the breakthroughs of tomorrow. That’s exactly the kind of thinking the world needs right now, and we are proud to play a small part in the promising careers of these winners and finalists.” Dr. Hillis works in the lab of Professor Matthew Vander Heiden, Director of the Koch Institute at MIT, studying aspects of metabolism that are limiting for cell proliferation in different contexts in order to translate findings in cancer cell metabolism into novel cancer therapies. Dr. Hillis proposed an exciting approach to study endometriosis, a highly prevalent condition in women that causes significant medical consequences, including chronic pain. Mr. Mantena is currently in the lab of Professor Soumya Raychaudhuri at Brigham and Women’s Hospital applying single-cell genomics approaches to study the adaptive immune system. For his proposal, Mr. Mantena was intrigued by the interesting phenomenon that cells in our thymus, which is responsible for important aspects of immune function, decrease competence with age. He wants to better understand this and proposed some exciting approaches to unravel this biological process and understand its implications for disease. "The Regeneron Prize prompts early career scientists to solve a problem that is important to them. We look for originality and creativity on the one hand, and practicality on the other. In particular, we’re trying to find young scientists who ask scientifically and medically important questions, alongside the ability to design a research plan capable of answering those questions," said David J. Glass, M.D., Vice President of Research, and Chair of the Postdoctoral Program at Regeneron. Inspiring and preparing young people to pursue STEM careers is a core focus of Regeneron’s social impact work. Founded and led by physician-scientists, Regeneron is deeply committed to advancing the next generation of innovators who will tackle society’s toughest challenges. Since its inception in 2013, the Regeneron Prize has provided nearly $2 million in awards to early-career scientists. Since 2020, Regeneron’s broader STEM initiatives have reached more than 3.25 million students, including through flagship high school science competitions like the Regeneron Science Talent Search and the Regeneron International Science & Engineering Fair. Requests for applications for the Regeneron Prize are distributed to academic institutions each December. Regeneron asks institutions to nominate two graduate students and two postdoctoral fellows. In addition to the dream project proposals, submissions must include a curriculum vitae and samples of publications that enable the selection committee to review each nominee's scholarly productivity. For more information, please email science.education@regeneron.com. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.  Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF). For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Media Contacts: Tara Naugle, Regeneron914-648-9917 Tara.Naugle@Regeneron.com

Related News